It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Dilated cardiomyopathy (DCM) is a fatal heart disease characterized by left ventricular dilatation and cardiac dysfunction. Recent genetic studies on DCM have identified causative mutations in over 60 genes, including RBM20, which encodes a regulator of heart-specific splicing. DCM patients with RBM20 mutations have been reported to present with more severe cardiac phenotypes, including impaired cardiac function, atrial fibrillation (AF), and ventricular arrhythmias leading to sudden cardiac death, compared to those with mutations in the other genes. An RSRSP stretch of RBM20, a hotspot of missense mutations found in patients with idiopathic DCM, functions as a crucial part of its nuclear localization signals. However, the relationship between mutations in the RSRSP stretch and cardiac phenotypes has never been assessed in an animal model. Here, we show that Rbm20 mutant mice harboring a missense mutation S637A in the RSRSP stretch, mimicking that in a DCM patient, demonstrated severe cardiac dysfunction and spontaneous AF and ventricular arrhythmias mimicking the clinical state in patients. In contrast, Rbm20 mutant mice with frame-shifting deletion demonstrated less severe phenotypes, although loss of RBM20-dependent alternative splicing was indistinguishable. RBM20S637A protein cannot be localized to the nuclear speckles, but accumulated in cytoplasmic, perinuclear granule-like structures in cardiomyocytes, which might contribute to the more severe cardiac phenotypes.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Tokyo Medical and Dental University (TMDU), Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130); Tokyo Medical and Dental University (TMDU), Department of Cardiovascular Medicine, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130)
2 Tokyo Medical and Dental University (TMDU), Department of Cardiovascular Medicine, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130)
3 Tokyo Medical and Dental University (TMDU), Laboratory of Molecular Neuroscience, Medical Research Institute, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130)
4 Tokyo Medical and Dental University (TMDU), Laboratory of Gene Expression, Medical Research Institute, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130)
5 Tokyo Medical and Dental University (TMDU), Department of Molecular Pathology, Graduate School of Medical and Dental Sciences, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130)
6 Osaka University, Graduate School of Frontier Biosciences, Suita, Japan (GRID:grid.136593.b) (ISNI:0000 0004 0373 3971)
7 Tokyo Medical and Dental University (TMDU), Department of Bio-informational Pharmacology, Medical Research Institute, Tokyo, Japan (GRID:grid.265073.5) (ISNI:0000 0001 1014 9130)